PMID- 34497757
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210910
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - YY1 Promotes Telomerase Activity and Laryngeal Squamous Cell Carcinoma 
      Progression Through Impairment of GAS5-Mediated p53 Stability.
PG  - 692405
LID - 10.3389/fonc.2021.692405 [doi]
LID - 692405
AB  - Yin Yang 1 (YY1) is a key transcription factor that exerts functional roles in 
      the cell biological process of various cancers. The current study aimed to 
      elucidate the role and mechanism of YY1 in laryngeal squamous cell carcinoma 
      (LSCC). YY1 mRNA and protein expression in human LSCC cell lines was detected by 
      RT-qPCR and Western blot analysis. An interaction of YY1, GAS5, and p53 protein 
      stability was predicted and confirmed by bioinformatics, ChIP, Co-IP, RIP, and 
      FISH assays. Following loss- and gain-function assays, LSCC cell proliferation, 
      colony formation, cell cycle, telomere length and telomerase activity were 
      evaluated by CCK-8 assay, colony formation assay, flow cytometry, and PCR-ELISA, 
      respectively. Nude mice were xenografted with the tumor in vivo. LSCC cell lines 
      presented with upregulated expression of YY1, downregulated GAS5 expression, and 
      decreased p53 stability. YY1 inhibited the expression of GAS5, which in turn 
      recruited p300 and bound to p53, thus stabilizing it. Moreover, YY1 could 
      directly interact with p300 and suppressp53 stability, leading to enhancement of 
      cell proliferation, telomere length and telomerase activity in vitro along with 
      tumor growth in vivo. Collectively, YY1 can stimulate proliferation and 
      telomerase activity of LSCC cells through suppression of GAS5-dependent p53 
      stabilization or by decreasing p53 stability via a direct interaction with p300, 
      suggesting that YY1 presents a therapeutic target as a potential oncogene in LSCC 
      development and progression.
CI  - Copyright (c) 2021 Wei, Liu, Jiang, Xu, Zhou and Kang.
FAU - Wei, Xudong
AU  - Wei X
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
AD  - The First School of Clinical Medicine, Gansu University of Chinese Medicine, 
      Lanzhou, China.
FAU - Liu, Fenglei
AU  - Liu F
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
FAU - Jiang, Xuelian
AU  - Jiang X
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
FAU - Xu, Xiaoyan
AU  - Xu X
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Gansu University of Chinese Medicine, 
      Lanzhou, China.
FAU - Zhou, Tianhao
AU  - Zhou T
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Gansu University of Chinese Medicine, 
      Lanzhou, China.
FAU - Kang, Chengfang
AU  - Kang C
AD  - Department of E.N.T., Gansu Provincial Hospital, Lanzhou, China.
AD  - The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210823
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8421032
OTO - NOTNLM
OT  - LncRNA growth arrest-specific 5
OT  - Yin Yang 1
OT  - laryngeal squamous cell carcinoma
OT  - p300
OT  - p53
OT  - telomerase activity
OT  - telomere length
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/10 06:00
MHDA- 2021/09/10 06:01
PMCR- 2021/01/01
CRDT- 2021/09/09 06:52
PHST- 2021/04/08 00:00 [received]
PHST- 2021/06/29 00:00 [accepted]
PHST- 2021/09/09 06:52 [entrez]
PHST- 2021/09/10 06:00 [pubmed]
PHST- 2021/09/10 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.692405 [doi]
PST - epublish
SO  - Front Oncol. 2021 Aug 23;11:692405. doi: 10.3389/fonc.2021.692405. eCollection 
      2021.